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MicroRNAs (MiRNAs) are involved in the regulation of 
several biological processes such as development, differentiation, 
metabolism, apoptosis and proliferation. Recently, it has been shown 
that deregulated expression of miRNAs are present in different 
human cancers, suggesting a potential role in carcinogenesis [1,2]. 
Recent evidence suggests that miRNAs may represent potential new 
therapeutic approaches in patients with drug resistance and drug 
induced toxicity [3]. MiRNAs may have therapeutic applications 
through two mechanisms. The first strategy involves the inhibition 
of oncogenic miRNAs by using miRNA antagonists (anti-miRNAs) 
resulting in up-regulation of genes that would be silenced by 
deregulated miRNAs. The second strategy involves the restoration in 
expression levels of tumor suppressor microRNA with miRNA mimics 
[1]. To date, several studies have shown that miRNA mimics and anti-
miRNAs may be useful to restore normal gene networks in different 
cancer cell lines and animal models, suggesting a new potential role in 
anti-cancer therapy.
MiRNAs deregulation in Colorectal Cancer (CRC) was reported 
for the first time in 2003, showing the down-regulation of miR-143 
and miR-145 in CRC tissues compared with normal tissues. Thereafter, 
numerous studies have reported different miRNA profiles in each CRC 
subtype [4].
Several evidences suggest that a small fraction of cells, termed 
Cell Stem Cells (CSCs), is responsible for the formation, growth and 
development of the tumor. Since this cancer cell population maintain 
the malignant potential and determine resistance to therapy, many 
tumors may progress because CSCs are resistant to cytotoxic drugs [5,6]. 
In a recent work, it has been shown that miR-451 was down-regulated 
in colonspheres with properties of CSCs from different colon cancer 
cells. Conversely, ectopic expression of miR-451 determined decreased 
tumorigenicity and self-renewal, and chemoresistance to irinotecan. 
Irinotecan causes inhibition of topoisomerase 1 by preventing DNA 
unwinding. Down-regulation of miR-451 increases the ATP-Binding 
Cassette Drug Transporter (ABCB1) resulting in irinotecan resistance. 
Reduced expression levels of miR-451 were detected in patients resistant 
to irinotecan-based first-line therapy. In 2009, it has been reported that 
miR-140 confers a methotrexate and 5-fluoroucil-resistant phenotype 
in colorectal CSC through the inibition of cell proliferation by targeting 
histone deacetylase 4 (HDAC4). The following year, the same authors 
showed that miRNA-215 enhances the chemoresistance of colorectal 
CSC to methotrexate and tomudex by inhibiting cell proliferation and 
inducing G2-arrest through the suppression of DTL expression [4].
Furthermore, Kurokawa et al. [7] detected the up-regulation of 
miR-19b and miR-21 in 5-fluorouracil (5FU)-resistant colon cancer 
cells. 5-FU resistance was related to alterations in the control of cell 
cycle progression caused by down-regulation of two putative gene 
targets: SFPQ and MYBL2 [7]. Therefore, miR-19b, miR- 21, miR-
140, miR-215 and miR-451 could be novel molecular markers useful 
to select patients resistant to therapy, but also serve as targets for the 
development of new possible therapeutic strategies to overcome the 
drug resistance.
Today, several studies focused on the use of miRNAs as possible 
therapeutic targets in chemotherapy resistance, by evaluating their 
aberrant expression in several chemoresistant tumors, in order to 
correct this dysregulation by means of miRNA-based drugs (anti-
miRNAs and miRNA mimics). This investigation is highly innovative 
and could have important clinical implications in understanding the 
molecular mechanisms responsible for chemoresistance in tumors. The 
identification of new possible molecular mechanisms of resistance to 
therapy could represent a new tool to select patients that could take 
benefit from this therapy. Recent advancements in the development 
of miRNA-based anti-cancer therapeutic approaches provided 
interesting results. However, despite the encouraging obtained data, the 
introduction of miRNAs in clinical practice is still too distant. There are 
still restrictions on the possible use of miRNAs as potential targets for 
the development of new therapeutic approaches. A possible limitation 
is to maintain target specificity, because miRNA targeting is sequence-
specific while gene silencing requires only a partial complementarity 
between miRNA and mRNA. Therefore, a specific miRNA-mediated 
therapy could induce unwanted gene alterations. Other limiting factor 
is to achieve high therapeutic efficiency due to the amplitude of target 
gene modulation and the number of cells that can be targeted. In 
conclusion, further investigations are needed to specifically evaluate 
these approaches invarious human tumors.
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